AstraZeneca clears latest hurdle for Alexion acquisition after EU clearance

In May, the UK’s Competition and Markets Authority (CMA) announced that it was reviewing AZ’s proposed takeover of Alexion. ... If the proposed acquisition is cleared by the CMA, AZ will make Alexion a dedicated rare disease business unit, and its

UK’s Competition and Markets Authority to review AZ/Alexion merger

The UK’s Competition and Markets Authority (CMA) is set to review AstraZeneca’s (AZ) planned takeover of rare diseases specialist Alexion. ... While the CMA has announced its intention to scrutinise the deal, the US Federal Trade Commission (FTC) has

UPDATE: AZ/Oxford University COVID-19 vaccine gets EU approval

CMA) for use in people aged 18 years and older. ... The European Medicines Agency (EMA) recommended the CMA on Friday, following an assessment conducted by its Committee for Medicinal Products for Human Use (CHMP) of all the available safety and efficacy

J&J’s one-dose COVID-19 vaccine granted EU authorisation

Johnson &Johnson’s (J&J) single-dose COVID-19 vaccine has scored a conditional marketing authorisation (CMA) from the European Commission, the company announced yesterday. . ... J&J submitted its vaccine for a CMA in the EU in February, basing the

AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine

The EMA announced today that it had received an application for conditional marketing authorisation (CMA) for AZ/Oxford’s COVID-19 vaccine. ... In December 2020, the EC also authorised a CMA for Pfizer/BioNTech’s COVID-19 vaccine, now known as

Strengthening business competition and reducing anti-competitive practices

A firm pharma focus. The CMA’s focus on the pharmaceutical industry is not surprising. ... cartel activities and serious abuses of a dominant position, which the CMA categorises.

Five things you didn't realise you already know about influencer marketing

The Advertising Standards Authority (ASA) and Competitions and Markets Authority (CMA) have been applying stricter guidelines and monitoring the industry more closely. ... Always seek advice from the agency you’re working with or directly from the ASA

Stakeholder dialogue in Europe’s adaptive pathways pilot

The use of real-world evidence (RWE) as a complement to clinical trial data to support reimbursement decisions after Conditional Marketing Authorisation (CMA) is granted.

Healthcare systems

Drug R&D